In ₹ Crore except Per Share Latest Annual | AJANTPHARM FY26 | ALKEM FY26 | IPCALAB FY26 | TORNTPHARM FY26 | Peer Median | |
|---|---|---|---|---|---|---|
| Valuation — at last close | ||||||
| P/E | 41.88× | ◆ 26.55× | 43.84× | 77.05× | 43.84× -4% | |
| P/B | 9.80× | ◆ 4.26× | 5.25× | 9.48× | 5.25× +87% | |
| EV/EBITDA | 31.49× | ◆ 20.54× | 25.10× | 39.37× | 25.10× +25% | |
| Market Cap | ₹44,374 Cr | ₹61,102 Cr | ₹50,032 Cr | ₹1.67L Cr | ₹61,102 Cr -27% | |
| Growth | ||||||
| Revenue CAGR 3Y | 13.37% | 8.25% | ◆ 15.60% | 13.27% | 13.27% +1% | |
| Revenue CAGR 5Y | ◆ 13.54% | 10.09% | 12.22% | 11.80% | 11.80% +15% | |
| Net Income CAGR 3Y | 21.55% | 32.67% | ◆ 35.20% | 19.75% | 32.67% -34% | |
| Revenue YoY (latest Q) | 24.82% | 10.95% | 20.76% | ◆ 54.85% | 20.76% +20% | |
| Net Income YoY (latest Q) | 30.89% | -22.00% | ◆ 82.18% | 3.28% | 3.28% +842% | |
| Profitability | ||||||
| EBITDA Margin | 25.58% | 20.43% | 20.51% | ◆ 32.61% | 20.51% +25% | |
| Net Income Margin | ◆ 19.37% | 15.98% | 12.27% | 15.29% | 15.29% +27% | |
| Return on Common Equity | ◆ 23.33% | 16.04% | 11.98% | 12.30% | 12.30% +90% | |
| Return on Capital Employed | ◆ 25.78% | 16.30% | 15.51% | 9.56% | 15.51% +66% | |
| Return on Assets | ◆ 17.16% | 11.26% | 9.57% | 4.82% | 9.57% +79% | |
| Credit & Quality | ||||||
| Total Debt/Equity | ◆ 0.05× | 0.11× | 0.07× | 0.84× | 0.11× -55% | |
| Interest Coverage | ◆ 75.83× | 16.32× | 20.55× | 8.94× | 16.32× +365% | |
| Scale — latest FY | ||||||
| Revenue / Total Income | ₹5,453 Cr | ₹14,712 Cr | ₹9,646 Cr | ₹13,980 Cr | ₹13,980 Cr -61% | |
| Net Income | ₹1,056 Cr | ₹2,351 Cr | ₹1,184 Cr | ₹2,138 Cr | ₹2,138 Cr -51% | |
| Total Assets | ₹6,155 Cr | ₹20,873 Cr | ₹12,370 Cr | ₹44,312 Cr | ₹20,873 Cr -71% | |
| EPS | ₹84.53 | ₹192.51 | ₹44.98 | ₹63.92 | ₹63.92 +32% | |
| Book Value per Share | ₹361.16 | ₹1,200.25 | ₹375.41 | ₹519.56 | ₹519.56 -30% | |